Merck & Co Inc

Merck’s 13‑F HR filing reveals its stake in early‑stage biotech, spotlighting Alector’s Alzheimer’s Phase‑III success and Carisma’s CAR‑T trials, while the company’s life‑science guidance boost drives modest stock gains.

Merck’s acquisition of Terns Pharmaceuticals clears a key antitrust hurdle, potentially boosting its specialty drug portfolio and valuation while navigating Medicare reimbursement and breakthrough therapy benefits.

Merck’s share dip amid a tech rally shows pharma’s slower momentum; insights on its vaccine tie‑ups, R&D spend and precision‑medicine prospects guide investors.

Merck’s MRK stock faces a temporary XETR outage, halting German trading—investors should monitor the pause and its impact on dividend‑focused ETFs.

Merck’s tariff‑exemption deal, KEYTRUDA® fast‑track expansion and helium‑supply vigilance reveal how the pharma giant balances U.S. pricing, oncology innovation and global supply risks.

Merck’s strategic moves—from long‑term HPV vaccine data to a Keytruda‑AI combo—aim to secure premium pricing, fend off generics, and grow precision oncology revenue.

Merck’s diversified portfolio thrives on oncology growth, solid cash flow, and digital health innovation—yet faces trials, pricing, and biosimilar risks that shape investor confidence.

Merck & Co. stays steady on the NYSE while the pharmaceutical market expands, with oncology breakthroughs and rising specialty therapeutics shaping future growth.

Merck’s Phase III wins for Keytruda + WELIREG and Keytruda + Padcev could boost kidney‑cancer and bladder‑cancer sales by over $1 billion, reshaping the oncology landscape.

Merck’s share dip mirrors a market sell‑off, yet new KEYTRUDA data for ovarian cancer bolsters its oncology pipeline and investor confidence.